Scalper1 News
Big-cap biotechs Celgene (CELG) and Alexion Pharmaceuticals (ALXN) both modestly beat Q2 estimates and raised their guidance Thursday morning, but their shares were falling in the stock market today as Wall Street seemed to hope for more. Celgene’s Q2 earnings rose 18% over the year-earlier quarter to 90 cents a share, beating consensus by a penny. Sales increased 17% to $1.87 billion, about $20 million above estimates. The company added $100 Scalper1 News
Scalper1 News